Phase 3 Recruiting Network
This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Paclitaxel is in a class of medicat…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT05929768
Sites in California: - Kaiser Permanente-Anaheim — Anaheim, California
- Mission Hope Medical Oncology - Arroyo Grande — Arroyo Grande, California
- PCR Oncology — Arroyo Grande, California
- Sutter Auburn Faith Hospital — Auburn, California
- Sutter Cancer Centers Radiation Oncology Services-Auburn — Auburn, California
Phase 3 Recruiting Academic/Other
This phase III trial compares 6 months of human epidermal growth factor receptor 2 (HER2)-targeted therapy to 12 months of HER2-targeted therapy for the treatment of HER2-positive (+) breast cancer in patients that had a pathologic complet…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT06876714
Sites in California: - Mission Hope Medical Oncology - Arroyo Grande — Arroyo Grande, California
- Tower Cancer Research Foundation — Beverly Hills, California
- Mercy Cancer Center - Carmichael — Carmichael, California
- Mercy San Juan Medical Center — Carmichael, California
- Enloe Medical Center — Chico, California
Phase 3 Recruiting Academic/Other
NRG-CC015 is a prospective, randomized phase III clinical trial to evaluate the efficacy of two distinct digital approaches for delivering a mindfulness-based intervention: a live, instructor-led version delivered over Zoom (MAPs LO), and …
Sponsor: NRG Oncology
NCT ID: NCT06748222
Sites in California: - Kaiser Permanente-Deer Valley Medical Center — Antioch, California
- AIS Cancer Center at San Joaquin Community Hospital — Bakersfield, California
- Marshall Cancer Center — Cameron Park, California
- Enloe Medical Center — Chico, California
- UC Irvine Health Cancer Center-Newport — Costa Mesa, California
Phase 3 Recruiting Industry
The purpose of this study is to learn about the safety and effects of the study medicine PF-07248144 when given along with fulvestrant for the possible treatment of HR-positive, HER2-negative advanced or metastatic breast cancer. HR-positi…
Sponsor: Pfizer
NCT ID: NCT07062965
Sites in California: - Los Angeles Cancer Network - Anaheim — Anaheim, California
- Los Angeles Cancer Network - Fountain Valley — Fountain Valley, California
- Los Angeles Cancer Network - (Admin Only / Central IDS) - No Patients — Glendale, California
- Los Angeles Hematology Oncology Medical Group — Los Angeles, California
- Los Angeles Cancer Network - Van Nuys — Los Angeles, California
Phase 3 Recruiting Industry
This is a Phase III open-label study to assess if camizestrant improves outcomes compared to standard adjuvant endocrine therapy for patients with ER+/HER2- early breast cancer with intermediate-high or high risk for disease recurrence who…
Sponsor: AstraZeneca
NCT ID: NCT05952557
Sites in California: - Research Site — Duarte, California
- Research Site — Fountain Valley, California
- Research Site — Greenbrae, California
- Research Site — Irvine, California
- Research Site — La Jolla, California
Phase 3 Recruiting Industry
The purpose of this open-label, multicenter, phase IIIb, single-arm study is to characterize the efficacy and safety of the combination of ribociclib and standard adjuvant endocrine therapy (ET) on invasive breast cancer-free survival (iBC…
Sponsor: Novartis Pharmaceuticals
NCT ID: NCT05827081
Sites in California: - Beverly Hills Cancer Center — Beverly Hills, California
- Onco Inst of Hope and Innovation — Cerritos, California
- City of Hope National Medical — Duarte, California
- Providence Medical Foundation — Fullerton, California
- Palo Alto Medical Foundation — Mountain View, California
Phase 3 Recruiting Industry
This is a Phase III, randomised, open-label, 3-arm, multicentre, international study assessing the efficacy and safety of Dato-DXd with or without durvalumab compared with investigator's choice chemotherapy in combination with pembrolizuma…
Sponsor: AstraZeneca
NCT ID: NCT06103864
Sites in California: - Research Site — Duarte, California
- Research Site — Glendale, California
- Research Site — Sacramento, California
- Research Site — Santa Rosa, California
Phase 3 Recruiting Industry
This is a Phase III, randomized, open-label multicenter study that will evaluate the efficacy and safety of giredestrant compared with fulvestrant, both in combination with the investigator's choice of a CDK4/6 inhibitor (palbociclib, ribo…
Sponsor: Hoffmann-La Roche
NCT ID: NCT06065748
Sites in California: - Sutter Auburn Faith Hospital — Auburn, California
- La Hematology Oncology Medical Group — Glendale, California
- Marin Cancer Care Inc — Greenbrae, California
- Kaiser Permanente - Harbor City — Harbor City, California
- USC Norris Comprehensive Cancer Center — Los Angeles, California
Phase 3 Recruiting Academic/Other
This phase III trial compares proton craniospinal irradiation (pCSI) to involved-field radiation therapy (IFRT) for the treatment of breast or non-small cell lung cancer that has spread from where it first started to the cerebrospinal flui…
Sponsor: NRG Oncology
NCT ID: NCT06500481
Sites in California: - UC San Diego Health System - Encinitas — Encinitas, California
- UC San Diego Moores Cancer Center — La Jolla, California
- UC San Diego Medical Center - Hillcrest — San Diego, California
- California Protons Cancer Therapy Center — San Diego, California
Phase 3 Recruiting Industry
The purpose of this study is to compare sacituzumab tirumotecan as a single agent, and in combination with pembrolizumab, versus Treatment of Physician's Choice (TPC) in participants with hormone receptor positive/human epidermal growth fa…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06312176
Sites in California: - Providence Medical Foundation-Oncology ( Site 0020) — Fullerton, California
- Moores Cancer Center ( Site 0059) — La Jolla, California
- Cancer and Blood Specialty Clinic ( Site 0001) — Los Alamitos, California
Phase 3 Recruiting Industry
This is a prospective, randomized, double-blinded, placebo-controlled, multi-center, Phase 3 study of GLSI-100 immunotherapy in HLA-A\*02 positive and HER2/neu positive subjects who are at high risk for disease recurrence and have complete…
Sponsor: Greenwich LifeSciences, Inc.
NCT ID: NCT05232916
Sites in California: - City of Hope - Duarte Cancer Center — Duarte, California
- Providence St. Jude Medical Center - Virginia K. Crosson Cancer Center — Fullerton, California
- City of Hope - Orange County Lennar Foundation Cancer Center — Irvine, California
- University of California San Diego - Moores Cancer Center — La Jolla, California
- University of Southern California - Norris Comprehensive Cancer Center — Los Angeles, California
Phase 2, Phase 3 Recruiting Industry
The purpose of this study is to assess the efficacy and safety of iza-bren, a bi-specific antibody-drug conjugate against EGFR and HER3 with a topoisomerase inhibitor payload versus treatment of physician's choice (TPC) (paclitaxel, nab-pa…
Sponsor: Bristol-Myers Squibb
NCT ID: NCT06926868
Sites in California: - Helios Clinical Research — Cerritos, California
- Local Institution - 0307 — Cerritos, California
- Local Institution - 0308 — Cerritos, California
- Local Institution - 0309 — Cerritos, California
- Local Institution - 0311 — Long Beach, California
Phase 3 Recruiting Industry
This study will evaluate the efficacy and safety of the combination of inavolisib plus a cyclin-dependent kinase 4 and 6 inhibitor (CDK4/6i) and letrozole versus placebo plus a CDK4/6i and letrozole in the first-line setting in participant…
Sponsor: Hoffmann-La Roche
NCT ID: NCT06790693
Sites in California: - Disney Family Cancer Center — Burbank, California
- Scripps Health — La Jolla, California
- Cancer and Blood Specialty Clinic — Los Alamitos, California
- Ellison Institute of Technology — Los Angeles, California
- Palo Alto Medical Foundation Research Center — Palo Alto, California
Phase 3 Recruiting Industry
This phase 3 clinical trial compares the efficacy and safety of palazestrant with ribociclib to letrozole and ribociclib in women and men who have not received prior systemic anti-cancer treatment for advanced breast cancer.
Sponsor: Olema Pharmaceuticals, Inc.
NCT ID: NCT07085767
Sites in California: - Clinical Trial Site — Santa Barbara, California
Phase 2 Recruiting NIH
This ComboMATCH patient screening trial is the gateway to a coordinated set of clinical trials to study cancer treatment directed by genetic testing. Patients with solid tumors that have spread to nearby tissue or lymph nodes (locally adva…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05564377
Sites in California: - PCR Oncology — Arroyo Grande, California
- Mercy Cancer Center - Carmichael — Carmichael, California
- Mercy San Juan Medical Center — Carmichael, California
- Epic Care-Dublin — Dublin, California
- Mercy Cancer Center - Elk Grove — Elk Grove, California
Phase 1, Phase 2 Recruiting Industry
This is a multicenter, Phase 1b/2 trial in participants with estrogen receptor positive/human epidermal growth factor receptor 2 negative (ER+/HER2-) advanced/metastatic breast cancer. The phase 1b part of the trial will determine the reco…
Sponsor: Stemline Therapeutics, Inc.
NCT ID: NCT05563220
Sites in California: - OPN Healthcare (Arcadia Location) — Arcadia, California
- City of Hope National Medical Center — Duarte, California
- Glendale Adventist — Glendale, California
- OPN Healthcare (Los Alamitos Location) — Los Alamitos, California
- Cedars Sinai — Los Angeles, California
Phase 1, Phase 2 Recruiting Industry
This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1303/BNT323 in subjects with advanced solid tumors that express HER2.
Sponsor: DualityBio Inc.
NCT ID: NCT05150691
Sites in California: - Helios Clinical Research — Cerritos, California
- California Research Institute — Los Angeles, California
- Sharp Memorial Hospital — San Diego, California
Phase 2 Recruiting Industry
PUMA-ALI-1201 is a randomized, dose optimization, multicenter, Phase 2 study of alisertib administered in combination with endocrine therapy in participants with pathology-confirmed HR-positive/HER2-negative metastatic breast cancer (MBC) …
Sponsor: Puma Biotechnology, Inc.
NCT ID: NCT06369285
Sites in California: - Beverly Hills Cancer Center — Beverly Hills, California
- MemorialCare Orange Coast Medical Center — Fountain Valley, California
- City of Hope at Orange County Lennar Foundation Cancer Center — Irvine, California
- LA Cancer Network — Los Angeles, California
- UCLA Department of Medicine - Hematology/Oncology — Los Angeles, California
Phase 1, Phase 2 Recruiting Industry
Study STX-478-101 (LY4064809) is a multipart, open-label, phase 1/2 study evaluating the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of STX-478 (LY4064809) in participants with advanced solid tumors with…
Sponsor: Eli Lilly and Company
NCT ID: NCT05768139
Sites in California: - Ellison Clinic at Saint John's — Los Angeles, California
- UCSF Medical Center at Mission Bay — San Francisco, California
Phase 1, Phase 2 Recruiting Industry
The primary objectives of the study are: (1) in the dose-escalation part: to evaluate safety and tolerability and to determine the recommended Phase 2 dose (RP2D) of farletuzumab ecteribulin (MORAb-202) in participants with selected tumor …
Sponsor: Eisai Inc.
NCT ID: NCT04300556
Sites in California: - Stanford Women's Cancer Center — Palo Alto, California
Phase 2 Recruiting Industry
The purpose of this study is to see if zanidatamab is safe and effective, when combined with chemotherapy, in treating people who has Human Epidermal Growth Factor Receptor 2 (HER2)-positive, early-stage breast cancer
Sponsor: Jazz Pharmaceuticals
NCT ID: NCT07102381
Sites in California: - Oncology Institute — Long Beach, California
Phase 2 Recruiting Industry
This study is designed to assess the efficacy and safety of ifinatamab deruxtecan (I-DXD) in the following tumor types: endometrial cancer (EC); head and neck squamous cell carcinoma (HNSCC); pancreatic ductal adenocarcinoma (PDAC); colore…
Sponsor: Daiichi Sankyo
NCT ID: NCT06330064
Sites in California: - Los Angeles Cancer Network — Los Angeles, California
- Valkyrie Clinical Trials — Los Angeles, California
- Pih Health Hematology Medical Oncology — Whittier, California
Phase 2 Recruiting Industry
This study is a multicenter, two-stage clinical trial to evaluate the efficacy and safety of utidelone in combination with capecitabine in patients with HER2-negative breast cancer with brain metastases. Patients will be enrolled to receiv…
Sponsor: Biostar Pharma, Inc.
NCT ID: NCT06764940
Sites in California: - City of Hope--Duarte — Duarte, California
- Cancer & Blood Research Center, LLC — Los Alamitos, California
- Univ. of California Los Angeles — Los Angeles, California
- FOMAT Medical Research (Network) — Oxnard, California
- Scripps Health — San Diego, California
Phase 1, Phase 2 Recruiting Industry
This is an umbrella study evaluating the efficacy and safety of multiple treatment combinations in participants with metastatic or inoperable locally advanced breast cancer. The study will be performed in two stages. During Stage 1, six co…
Sponsor: Hoffmann-La Roche
NCT ID: NCT03424005
Sites in California: - City of Hope — Duarte, California
- University of California San Diego Medical Center — La Jolla, California
- Stanford Cancer Institute — Stanford, California
Phase 1, Phase 2 Recruiting Industry
This is a first in human study in patients with advanced or metastatic solid tumors known to have an MTAP deletion. The first part of the study is an open-label, dose escalation and the second part is an open label dose expansion in specif…
Sponsor: Tango Therapeutics, Inc.
NCT ID: NCT05732831
Sites in California: - Stanford University — Palo Alto, California